Skip to content

CancerIndexthe global index of cancer

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Pulse Data updates Year in cancer Taxonomy Countries Compare Trial intelligence Trial map Drug pipeline Sources Methodology About Trust & policies Data downloads Developers (API)

Loading cancer entity…

CancerIndex

CancerIndex is a research and information platform. It is not a physician, does not diagnose, and does not recommend treatment. Population statistics do not predict individual outcomes.

Every number links to its source and retrieval date. Derived metrics carry a formula version. AI-generated synthesis is not enabled in this phase; all content is database-grounded.

About Trust & policies Data explorer Data downloads Pulse Data update log Developers (API)Sources Methodology Taxonomy Countries Compare Contact · contact@spboucher.ai Status

© 2026 CancerIndex · built and maintained by Simon-Pierre Boucher · contact contact@spboucher.ai · hosted on MacLustr (www.maclustr.io). Source data remains under the license of each provider — see /sources.

Liver Epithelial Neoplasm — Research · CancerIndex

Cancers
Neoplasm
Neoplasm by Morphology
Epithelial Neoplasm
Liver Epithelial Neoplasm

Cancer Family

Liver Epithelial Neoplasm

CI-CAN-00000217Explore in graph →

Non-malignant784 active trials14 approved drugs17 evidence items

NCIt: C7106

Overview
Statistics
Survival
Genomics20
Variants & evidence17
Drugs10
Trials3369
Research
Rankings
Sources & provenance

Research activity

PubMed record counts

Each count is the number of PubMed records returned by the exact query shown, at the time it was run. Counts are research-activity signals, not quality measures.

Data not yet available

No PubMed query has been run for this entity. Counts require a MeSH-anchored query built from the entity's terminology mappings; the query string is stored with each count so it can be reproduced.

What CancerIndex knows

Trials tab
Methodology: publication counts

Literature

Linked publications (31)

Publications linked to this entity or its descendants, newest first, 25 per page. Link method and validation status are shown; 'candidate' links have not been reviewed.

pubmedProvenance

Source: PubMed (NLM)
Dataset: PubMed E-utilities
Retrieved: Sep 8, 2026
Layer: normalized (units and labels harmonized; values unchanged)

PublishedShowing 1–25 of 31 publications · bibliographic data as recorded by PubMed; abstracts are not reproduced.

Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study.
· Lancet Oncol · 2020 · PMID 32203698 · validated civic_curation pubmed
DNAJB1-PRKACA is specific for fibrolamellar carcinoma.
· Mod Pathol · 2015 · PMID 25698061 · validated civic_curation pubmed
Detection of a recurrent DNAJB1-PRKACA chimeric transcript in fibrolamellar hepatocellular carcinoma.
· Science · 2014 · PMID 24578576 · validated civic_curation pubmed
Unique genomic profile of fibrolamellar hepatocellular carcinoma.
· Gastroenterology · 2015 · PMID 25557953 · validated civic_curation pubmed
First-in-Human Phase I Study of Fisogatinib (BLU-554) Validates Aberrant FGF19 Signaling as a Driver Event in Hepatocellular Carcinoma.
· Cancer Discov · 2019 · PMID 31575541 · validated civic_curation pubmed
High expression of HEF1 predicts a poorer prognosis of hepatocellular carcinoma: A retrospective study.
· Mol Clin Oncol · 2016 · PMID 26893853 · validated civic_curation pubmed
Evaluation of KIF23 variant 1 expression and relevance as a novel prognostic factor in patients with hepatocellular carcinoma.
· BMC Cancer · 2015 · PMID 26674738 · validated civic_curation pubmed

Showing 1–25 of 31 publications

← Previous
1
2
Next →

GNAS1 T393C polymorphism is associated with clinical course in patients with intrahepatic cholangiocarcinoma.

· Neoplasia · 2007 · PMID 17356712 · validated civic_curation pubmed

Derazantinib (ARQ 087) in advanced or inoperable FGFR2 gene fusion-positive intrahepatic cholangiocarcinoma.

· Br J Cancer · 2019 · PMID 30420614 · validated civic_curation pubmed

Activation of JNK and high expression level of CD133 predict a poor response to sorafenib in hepatocellular carcinoma.

· Br J Cancer · 2012 · PMID 22596232 · validated civic_curation pubmed

A phase II study of the efficacy and safety of the combination therapy of the MEK inhibitor refametinib (BAY 86-9766) plus sorafenib for Asian patients with unresectable hepatocellular carcinoma.

· Clin Cancer Res · 2014 · PMID 25294897 · validated civic_curation pubmed

Impressive response to dual BRAF and MEK inhibition in patients with BRAF mutant intrahepatic cholangiocarcinoma-2 case reports and a brief review.

· J Gastrointest Oncol · 2016 · PMID 28078132 · validated civic_curation pubmed

Dramatic response to dabrafenib and trametinib combination in a BRAF V600E-mutated cholangiocarcinoma: implementation of a molecular tumour board and next-generation sequencing for personalized medicine.

· Ecancermedicalscience · 2014 · PMID 25435907 · validated civic_curation pubmed

Phase II Study of Erdafitinib in Patients With Tumors With Fibroblast Growth Factor Receptor Mutations or Fusions: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol K2.

· JCO Precis Oncol · 2024 · PMID 38603650 · validated civic_curation pubmed

Activating JAK1 mutation may predict the sensitivity of JAK-STAT inhibition in hepatocellular carcinoma.

· Oncotarget · 2016 · PMID 26701727 · validated civic_curation pubmed

Isocitrate Dehydrogenase Mutations Confer Dasatinib Hypersensitivity and SRC Dependence in Intrahepatic Cholangiocarcinoma.

· Cancer Discov · 2016 · PMID 27231123 · validated civic_curation pubmed

Chen L et al. Nature 2024

· 2024 · PMID 38355797 · validated cbioportal_study pubmed

Schulze et al. Nat Genet 2013

· 2013 · PMID 25822088 · validated cbioportal_study pubmed

Darren et al. JCO Precis Oncol 2023

· 2023 · PMID 37769223 · validated cbioportal_study pubmed

Charlotte Ng et al. Nat Commun. 2022

· 2022 · PMID 35508466 · validated cbioportal_study pubmed

Song, Yi et al. Clin Cancer Res 2024

· 2024 · PMID 38864854 · validated cbioportal_study pubmed

Zheng et al. PLOS One 2018

· 2018 · PMID 30052636 · validated cbioportal_study pubmed

Harding et al. Clin Cancer Res 2018

· 2018 · PMID 30373752 · validated cbioportal_study pubmed

Xue et al. Cancer Cell 2019

· 2019 · PMID 31130341 · validated cbioportal_study pubmed

Sia et al. Nature Commun 2015

· 2015 · PMID 25608663 · validated cbioportal_study pubmed